|
Microbe
|
Type of non-susceptibility
|
Surveillance Area
|
Trends in proportions of non-susceptibility (Time period)
|
|---|
|
E. coli
|
Gentamicin non-susceptibility
|
Levanger Hospital
|
0.5% (2002–05)
|
3.3% (2010–13)
|
|
Iceland
|
2.9% (2010)
|
4.1% (2013)
|
|
Norway
|
0.6% (2003)
|
7.7% (2014)
|
|
EU/EEA
|
5.2% (2002)
|
9.9% (2013)
|
|
Bulgaria
|
15.8% (2003)
|
32.1% (2013)
|
|
E. coli
|
Resistance to 3rd generation cephalosporins
|
Levanger Hospital
|
0 (2002–05)
|
1.7% (2010–13)
|
|
Norway
|
1.5% (2008)
|
5.8% (2014)
|
|
EU/EEA
|
2.0% (2002)
|
12.6% (2013)
|
|
Bulgaria
|
24.8% (2010)
|
39.6% (2013)
|
|
S. aureus
|
MRSA
|
Levanger Hospital
|
0 (2002–05)
|
1.0% (2010–13)
|
|
Norway
|
0.3% (2002)
|
0.8% (2014)
|
|
EU/EEA
|
25.6% (2007)
|
18.0% (2013)
|
|
Malta
|
52.0% (2007)
|
51.8% (2013)
|
|
Romania
|
39.1% (2010)
|
64.5% (2013)
|
|
S. pneumoniae
|
PNSP
|
Levanger Hospital
|
0 (2002–05)
|
3.0% (2010–13)
|
|
Netherlands
|
2.0% (2010)
|
1.1% (2013)
|
|
Norway
|
0.9% (2002)
|
5.5% (2014)
|
|
Cyprus
|
41.7% (2010)
|
40.0% (2013)
|
- MRSA, meticillin-resistant Staphylococcus aureus; PNSP, penicillin non-susceptible pneumococci
- Proportions of non-susceptibility from the current study (Levanger Hospital) are compared with data from Norway (the national surveillance system [8, 30], the European Union/the European Economic Area (EU/EEA), and with countries which have extraordinary low or high proportions of non-susceptibility [7, 24, 25]
